Sagarika Basnet

Sagarika Basnet

Auto-generated profile, based on publicly available information

Sagarika Basnet

Department of Internal Medicine Kathmandu Medical College Kathmandu Nepal

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2025 in The Open Respiratory Medicine Journal
Verified
Journal Article
Open access
PDF file
VPVivek Paudyal
Vivek Paudyal
RTRubi Thapa
Rubi Thapa
SBSagarika Basnet
Sagarika Basnet
MSMunish Sharma
Munish Sharma
Salim SuraniSalim Surani
Salim Surani
JVJoseph Varon
Joseph Varon
Pulmonary Arterial Hypertension (PAH) is an uncommon condition with high mortality. It is an underrecognized condition both in developing and developed countries, especially in developing countries, due to a lack of advanced healthcare facilities and resources for timely diagnosis. More than half of the individuals diagnosed with PAH live less than five years after diagnosis. In recent years, tremendous advancements have been made in diagnostic and therapeutic strategies for PAH patients. Phosphodiesterase 5 (PDE5) inhibitors, endothelin receptor antagonists, and prostacyclin inhibitors in various forms (oral, inhaled, intravenous, or subcutaneous) have been the cornerstone of medical treatment. Atrial septostomy, heart and lung transplant, balloon pulmonary angioplasty, and pulmonary thromboendarterectomy are existing therapeutic options currently available. There has been a continuous effort to introduce newer therapies to improve life expectancy and modify disease. Newer therapies have shown promising results but require future data to guarantee long-term safety and efficacy. We aim to discuss a few of these critical updates in the constantly evolving field of PAH.